Form 4: Emergent BioSolutions Director Acquires 5,006 Shares

Emergent BioSolutions Inc. Director John D. Fowler Jr. acquired 5,006 shares of common stock through a restricted stock unit grant.

Summary

• Director John D. Fowler Jr. acquired 5,006 shares of Emergent BioSolutions Inc. common stock.
• The transaction occurred on March 3, 2026, at a price of $8.99 per share.
• These shares were granted as restricted stock units (RSUs) under the company's Stock Incentive Plan.
• The restricted stock units will vest in three annual installments, commencing on the day prior to the anniversary of the grant date, contingent upon continued service with the company.
• Each restricted stock unit represents the right to receive one share of common stock of Emergent BioSolutions Inc.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, as it represents routine director compensation that aligns interests, without indicating any significant operational or financial changes.

Positives

• The grant of restricted stock units to a director aligns management's interests with those of shareholders, as the value of the compensation is tied to the company's stock performance.
• The vesting schedule encourages long-term commitment and continued service from the director.

Future Outlook

The restricted stock units are scheduled to vest in three annual installments, beginning on the day prior to the anniversary of the grant date, assuming continued service with the company.

Industry Context

StockSavvy.ai notes that the grant of restricted stock units to directors is a common and standard practice across various industries for executive and board compensation, designed to align the interests of insiders with long-term shareholder value.

Comparison to Industry Standards

• This RSU grant is consistent with typical equity compensation structures observed in publicly traded companies, where directors receive stock-based awards to incentivize long-term performance and retention.
• The vesting schedule of three annual installments is a common approach to ensure continued service and commitment, comparable to practices at companies like Pfizer or Johnson & Johnson for their non-employee directors.

Related Party Transactions

• Grant of 5,006 restricted stock units to Director John D. Fowler Jr. as part of the company's Stock Incentive Plan, representing standard equity compensation.

Stakeholder Impact

• Shareholders: The director's interests are further aligned with shareholder value through increased equity ownership.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• The restricted stock units will vest in three annual installments, contingent on continued service with the company.

Key Dates

Recommendation

This Form 4 reports a routine equity compensation grant to a director, which is a standard practice for aligning insider interests with shareholders. It does not provide new information that would significantly alter the company's fundamental outlook or warrant a change in investment strategy, thus a 'hold' recommendation is appropriate.

Keywords

Emergent BioSolutions, EBS, Form 4, Insider Transaction, Restricted Stock Units, Director Compensation, Equity Grant